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Summary
Multiple Sclerosis (MS) is the most frequent chronic neurologic pathology diagnosed in young adults. The 
demyelinating process leads to axonal myelin loss, causing axonal and glial neuronal dysfunctions, clinically manifested 
by relapse. Transcranial magnetic stimulation (TMS) is a noninvasive method useful in assessing corticospinal tract 
dysfunctions in Multiple Sclerosis patients, by recording the prolonged central motor conduction time (CMCT), the 
increase of the motor threshold and also the reduction in amplitude of the motor evoked potential (MEP). Thus, stimulating 
the cortical motor area will determine a recordable response characteristic for the electrophysiological behavior of the 
pyramidal tract. We investigated 37 MS patients with relapse, manifesting by motor defi cit, performing TMS prior to 
receiving corticosteroids (1000 mg intravenous Methylprednisolone daily, for 5 days), 5 days afterwards and also after 
one month from the treatment. 26 patients presented both electrophysiological and clinical improvement after therapy, 
whereas 11 patients did not show any electrophysiological improvement, in spite of a slight amelioration of the symptoms. 
TMS proves to be a sensitive tool for investigating the relapse and the corticotherapy effi ciency. 
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Introduction
Multiple Sclerosis (MS) is characterized by 
infl ammation, demyelination and gliosis. The clinical 
value is attributed to the lesions that result depending 
on their dissemination in time and space. The relapse 
is the clinical and electrophysiologic expression of 
the demyelinating process. In MS the defi cits resulted 
during the relapse can be present for a certain period 
of time, with either partial or complete amelioration. 
One of the characteristics of MS is that a relapse can 
be associated with a totally different type of defi cit 
compared to the previous ones, thus in time, residual 
defi cits can add to the main clinical picture of the 
disease. 
In establishing a proper diagnosis, even though 
magnetic resonance imaging (MRI) is superior 
to evoked potential (EP), especially related to 
demyelinating lesions located periventricularly, EP 
are to be preferred in following the progression of 
the disease, due to their practical use in investigating 
nervous conduction. Subclinical lesions can be 
described this way, not to mention the possibility of 
future predicting of the long term course [1].
Transcranial magnetic stimulation (TMS) is a 
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modern and useful method, destined to investigate 
various neurological disorders such as MS, 
Parkinson’s disease, amyotrophic lateral sclerosis 
and other cerebrovascular diseases, available in its 
actual form since 1985 [5]. By the use of repetitive 
stimulation, it can be also used in treating depression 
as well as other conditions, therapeutic approaches 
being expected to be established in the closest future 
[9]. Synaptic long-term potentiation (LTP), the 
possibility of restoring membrane excitability for 
neurons that no longer posses a part of their synaptic 
inputs, explored by TMS, is another promising 
research direction, as it seems that the LTP reserve 
tends to contrast the progression of disabilitating 
defi cits in MS [2].
TMS is useful for examining the corticomotor 
conduction especially in the hand and leg of MS 
patients with motor defi cit, the idea of monitoring 
the effects of steroids on cortical excitability by 
investigating the motor evoked potential (MEP) 
already showing promising results [4,6,7].
The aim of the present study is to determine the 
MEP modifi cations of 37 Relapse Remitting MS 
(RRMS) patients during relapse, by performing TMS 
prior to, 5 days after and 1 month after the initiation 
of treatment with methylprednisolone.
Material and methods
We investigated 37 RRMS patients with relapse, 
with medium age of 37.6 ± 9.46 years. 9 patients 
presented motor defi cit on either right or left side of 
the body, 14 patients had motor defi cit manifesting 
through paraparesis, 11 patients accused sensory 
symptoms (paresthesias and formications in both 
upper and lower limbs) and a minimal hemiparetic 
defi cit, and 3 patients presented monoparetic motor 
defi cit. According to the affect of the pyramidal tract, 
the Expanded Disability Status Scale (EDSS) had 
different values: 14 patients with EDSS 2 (37.83%), 
8 patients with EDSS 2.5 (21.6%), 6 patients with 
EDSS 3 (16.1%), 5 patients with EDSS 3.5 (13.55%) 
and 4 patients with an EDSS of 6 (10.9%). The 
medium EDSS was 3.4±3.4. In the 37 patients group 
the EDSS varied from 2 to 6.
The patients with relapse were investigated by 
TMS prior to and after receiving corticosteroids 
(Methylprednisolone 1000 mg intravenous, daily, 
for 5 days). The TMS after corticotherapy consisted 
in examination after the 5 days, and after one month.
TMS was performed with a Magstim Rapid® 
device (Magstim Co. Ltd, Whitland, Dyfed, UK). 
We used the butterfl y shaped and the round coil. The 
butterfl y shaped coil has a diameter of 7 cm, and is 
able of generating a magnetic fi eld of up to 1.2 Tesla. 
The round coil generates a cone shaped magnetic 
fi eld, performing a diffuse stimulation. This is the 
reason why this particular coil is preferred in clinical 
practice for the stimulation of the cervical and lumbar 
areas. The MEP was collected from the abductor 
digiti minimi muscle and tibialis anterior muscle, 
using surface electrodes. 
In order to demonstrate the utility of TMS in 
following the effi cacy of corticotherapy in MS patients 
with relapse, we measured the motor conduction 
latency (MCL) and the central motor conduction time 
(CMCT) from the two cerebral hemispheres, before 
and after receiving corticosteroid treatment. For the 
central cerebral stimulation we used the butterfl y coil, 
stimulating in turn the right and the left hemispehere, 
and collecting information from the abductor digiti 
minimi muscle. The stimulation for the lower limbs 
was similar, with difference consisting in collecting 
the information from the tibialis anterior muscle. 
For the cervical and lumbar stimulations we used 
the round coil, stimulating at C7 respectively at L5 
level, and collecting information from abductor digiti 
minimi for the upper limbs, and from tibialis anterior 
for the lower limbs. 
The statistic analysis was performed by applying 
the Paired-Samples T Test statistic procedure, using 
SPSS 17 through Analyse – Compare Means – Paired 
Samples T Test protocol.
Results
The statistic analysis revealed an amelioration 
of the MEP latency and a discrete amelioration of 
the CMCT after stimulating the mentioned areas in 
26 patients. In 11 patients there were no latency or 
CMCT improvements, the values obtained possessing 
no statistic signifi cance.
For the upper limbs, the CMCT for the left 
hemisphere was 10.14±1.3 before corticotherapy, 
10.6 ± 0.67 5 days afterwards and 10.3±0.58 after 
one month. The MCL for the left hemisphere was 
24.85±0.96 miliseconds prior to corticotherapy, 
24.62±0.9 5 days after, and 23.58±1.17 after one 
month, with p<0.003.
The CMCT on the right hemisphere before 
corticotherapy 10.31±1.39, 5 days after corticotherapy 
10.46±1.19, and one month afterwards 10.25±1.04. 
The left cortical latency before the corticotherapy 
was 24.40±0.89; 5 days after: 23.66±0.70, and one 
month later 22.58±0.9, p<0.001.
At cervical level on the right, the values before 
corticotherapy were 13.04±0.33, 12.9±0.30 5 days 
after, and 12.59±0.3 after one month, with p<0.001.
At cervical level on the left, the values before 
the corticosteroid therapy were 12.36±0.41, 5 days 
after therapy 12.57±0.39 and 12.17±0.40 one month 
afterwards, with p<0.001.
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In the lower limbs, on the right, the cortical 
latency before corticotherapy was 34.3±2.7, 5 days 
after was 33.5±2.2 and one month later was 32.3±2, 
with p<0.003. On the left, before steroids the values 
were 33.96±2.6, 5 days later they were 33.4±2.3 and 
one month later 33±1.9, with p<0.003. The CMCT 
on the right side was 20.58±3.44 before therapy, 
20.3±3.1 5 days later, and 20.15±2.99 one month 
later. On the left side, the CMCT was 18.95±4.01 
before treatment, 18.92±3.7 5 days later and 18.6±3.1 
one month later.
At lumbar level on the right side the values were: 
12.92±0.6, 12.22±0.41 and 11.11±0.37, according to 
the three moments of measurement, with p<0.001.
At lumbar level on the left side, the values were: 
12.79±0.54 initially, 12.34±0.41 after 5 days, and 
11.27±0.4 one month later, with p<0.001. 
Among the 26 MS patients with relapse, a 
positive infl uence of the corticotherapy, with statistic 
signifi cance, is represented by the modifi cations of 
the MEP latencies both on the right and left, after 
5 days, respectively one month of corticosteroid 
Figure 1. Modifi cation of the MEP latency measured at cerebral level for the left hemisphere. The vertical column rep-
resents the latency’s values.
Figure 2. Modifi cation of MEP latency at left cerebral hemisphere level.
Figure 3. The modifi cation of the MEP latency at cervical level on the right.
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treatment, with p<0.05. O discrete infl uence of the 
corticotherapy can be also observed for the CMCT 
for both the upper and lower limbs for up to a month 
from treatment.
On the exploration of the lower limbs, the 
statistic signifi cant values related to MEP latency 
were obtained at cerebral level both on right and left, 
p<0.003. CMCT in the lower limbs was discreetly 
infl uenced by corticotherapy. 
Discussions
From an anatomical perspective, it is well known 
that the pyramidal tract is the efferent pathway of 
Figure 4. The modifi cation of the MEP latency at cervical level, one month after the corticotherpy.
Figure 5. MEP modifi cations at right lumbar level.
Figure 6. MEP modifi cations at left lumbar level.
Figure 7. The ameliorated/stationary patients ratio
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the frontal lobe, the 4th fi eld at this level possessing 
both motor and motor-analyzer functions. It is 
responsible for the analysis of sensitive excitations 
that arrive here, and sending them towards the spinal 
motoneurons. Thus, a lesion at this level will produce 
a controlateral hemiparesis.
TMS is a good way to evaluate corticospinal 
tract dysfunctions in MS patients by interpreting 
the prolonged CMCT, the increased threshold and 
also the reduction of MEP amplitudes. The CMCT 
is the amount of time required by neural impulse 
from the central nervous system (CNS) towards 
the muscles. So, it is a time unit depending on 
the excitation of cortical neurons, the conduction 
through the corticospinal or corticobulbar tract, 
and also on the cortical or spinal motoneuron 
excitation. The muscular response latencies as a 
result to cortical stimulation actually represent the 
sum between central and peripheral conduction 
units of time [14]. 
CMCT is known to be abnormal in 57-93% of 
MS patients. Its sensitivity for both improvement 
and worsening of the motor function make it a useful 
measurement to be assessed in TMS related studies 
[15]. 
TMS also allows the study of transcallosal 
inhibition, as the interhemispheric transmission is 
altered in MS patients. The pathological modifi cations 
at this level, the correlations with the clinical defi cits, 
as well as estimating the progression of the disease, 
are all markers to be assessed throughout TMS studies 
[10].
In our study, a positive infl uence of the 
corticotherapy was obtained by recording a modifi ed 
MEP latency both in the upper and lower limbs, 
with minimum ameliorations of CMCT, therefore, 
the 26 patients presenting both clinical and 
electrophysiological amelioration. 
Among the other 11 patients in which minimum 
electrophysiological improvement was observed, in 
spite of clinical obvious amelioration, there were no 
statistic signifi cant values obtained, especially related 
to the CMCT. 
Throughout the recent years TMS has emerged as a 
method to correlate the clinical manifestations during 
MS attacks and the disease progression with plasticity 
and chronic reorganization processes [3]. It has also 
been showing utility in assessing the relationship 
between steroid administration and improvement 
of symptoms, as similar results have been found by 
other authors [4,11,12,13]. Furthermore it proves its 
utility as an investigation technique for quantifying 
electrophysiological pyramidal tract anomalies, 
as well as representing a good way to monitor the 
evolution of MS [8]. 
Conclusions
The benefi t of corticotherapy in MS patients with 
relapse can be assessed by TMS. Signifi cant values 
suggesting post-therapy amelioration have been 
obtained at central level, with statistic signifi cance.
Stimulating the motor area will lead to a response, 
translated by the electrophysiological behavior of the 
pyramidal tract. We can consider that in MS, this 
actually represents the semiological basis of the TMS 
investigations, making this technique useful in the 
exploration of the pyramidal tract, and a possible way 
of building up an electrophysiological defi nition of 
the relapse.
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